

Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

HCC1806

RRID:CVCL_1258

Type: Cell Line

Proper Citation

RRID:CVCL_1258

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1258

Proper Citation: RRID:CVCL_1258

Description: Cell line HCC1806 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast acantholytic squamous cell carcinoma

Defining Citation: [PMID:9288768](#), [PMID:9833771](#), [PMID:9865903](#), [PMID:11314036](#), [PMID:12353263](#), [PMID:12800145](#), [PMID:19582160](#), [PMID:20070913](#), [PMID:20164919](#), [PMID:20679594](#), [PMID:21603256](#), [PMID:21778573](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:23601657](#), [PMID:24176112](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25892236](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30787054](#), [PMID:30835260](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#), [PMID:40300663](#)

Comments: Miscellaneous: Direct author submission of STR profile from Girard, Luc & Gazdar, Adi F., Population: African American., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Triple negative breast cancer (TNBC) cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCC1806

Synonyms: Hcc1806, HCC-1806, Hamon Cancer Center 1806

Cross References: BTO:BTO_0006395, CLO:CLO_0003644, EFO:EFO_0005373, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2335, BioGRID_ORCS_Cell_line:662, BioSample:SAMN03472709, BioSample:SAMN10988428, cancercellines:CVCL_1258, Cell_Model_Passport:SIDM00875, ChEMBL-Cells:ChEMBL3308135, ChEMBL-Targets:ChEMBL1075457, CLS:300467, Cosmic:687479, Cosmic:904367, Cosmic:907047, Cosmic:1047705, Cosmic:1287888, Cosmic:1460234, Cosmic:1603206, Cosmic:1935008, Cosmic-CLP:907047, DepMap:ACH-000624, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, FANTOM5_SSTAR:10717-10916, GDSC:907047, GEO:GSM217576, GEO:GSM219878, GEO:GSM344339, GEO:GSM344389, GEO:GSM350528, GEO:GSM378147, GEO:GSM783942, GEO:GSM844546, GEO:GSM844547, GEO:GSM847325, GEO:GSM847482, GEO:GSM887044, GEO:GSM888114, GEO:GSM1053713, GEO:GSM1172869, GEO:GSM1172960, GEO:GSM1374504, GEO:GSM1374505, GEO:GSM1669850, IARC_TP53:10273, KCB:KCB_2014032YJ, LiGeA:CCLE_250, LINCS_HMS:50211, LINCS_LDP:LCL-1960, PharmacDB:HCC1806_483_2019, PRIDE:PXD008222, PRIDE:PXD030304, Progenetix:CVCL_1258, PubChem_Cell_line:CVCL_1258, SLKBase:3534, Ubigen:YC-C073, Wikidata:Q54881605

ID: CVCL_1258

Record Creation Time: 20220427T220318+0000

Record Last Update: 20260829T233629+0000

Ratings and Alerts

No rating or validation information has been found for HCC1806.

No alerts have been found for HCC1806.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 590 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Bai Y, et al. (2026) Epigenetic Regulation of Chromosomal Instability by EZH2 Methyltransferase. Cancer discovery, 16(1), 135.

Cruz A, et al. (2026) Targeting TNBC: core-shell polycationic polyurea dendrimers with inherent anticancer activity. FEBS open bio, 16(5), 944.

Wang Z, et al. (2026) RAD51 succinylation regulates homologous recombination and contributes to the chemosensitivity in cancer. Molecular cell, 86(4), 585.

Nandi D, et al. (2026) Spermine Oxidase Serves as a Key Functional Node in Microbial Dysbiosis-Induced Breast Carcinogenesis. *Cancer research*, 86(8), 1920.

Li Z, et al. (2026) Exploration of precise classification and therapeutic targets of breast cancer based on genes related to neuro-cancer crosstalk. *Translational oncology*, 64, 102647.

MacLean MR, et al. (2026) Selective inhibition of ALDH1A3 impedes breast cancer growth and metastasis by blocking ALDH1A3-driven transcriptional programs. *iScience*, 29(3), 114863.

Dommer AP, et al. (2026) Cyclin E modulates vulnerability to CDC7 kinase inhibition. *Oncogenesis*, 15(1).

Hachey JS, et al. (2026) Exploring the 89Zr/177Lu Theranostic Pairing with an Extracellular Matrix-Targeted Radiopharmaceutical against Triple-Negative Breast Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(7), 1337.

Lin W, et al. (2026) FAM135B Deficiency Inhibits Cytotoxic T-cell Activity in Triple-Negative Breast Cancer by Blocking the IFI16-Dependent STING Pathway. *Cancer immunology research*, 14(2), 335.

Rampa DR, et al. (2026) Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(8), 1454.

Luo L, et al. (2026) CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction. *Nature communications*, 17(1), 619.

Xu Y, et al. (2026) Comprehensive single-cell metabolic profiling identifies targets to sensitize triple-negative breast cancer to chemo-immunotherapy. *Cell reports. Medicine*, 7(3), 102659.

Sun GS, et al. (2026) AK5 suppresses breast cancer progression and modulates anti-PD-L1 efficacy via the miR-182-5p/PD-L1 axis. *iScience*, 29(4), 115260.

Miao J, et al. (2025) KIF18A promotes chromosome congression in cooperation with CENP-E downstream of CENP-C. *Cell reports*, 44(11), 116515.

Abelman RO, et al. (2025) TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*.

Suresh S, et al. (2025) PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1/2 and MTAP status in breast cancer cells. *Scientific reports*, 15(1), 36766.

Smoak CN, et al. (2025) ZYS-1 is not an ADAR1 inhibitor. *RNA (New York, N.Y.)*, 31(12), 1703.

Jeon JH, et al. (2025) Interplay between malic enzyme 2, de novo serine synthesis, and the malate-aspartate shuttle drives metabolic adaptation in triple-negative breast cancer.

Cancer & metabolism, 13(1), 42.

Mahajan M, et al. (2025) The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer. *Molecular cancer therapeutics*, 24(9), 1308.

Wang Z, et al. (2025) CD36-mediated endocytosis of proteolysis-targeting chimeras. *Cell*, 188(12), 3219.